Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDX..L Regulatory News (DX.)

  • There is currently no data for DX.

Amendment to Performance Share Plan

14 Dec 2022 10:45

RNS Number : 6814J
DX (Group) PLC
14 December 2022
 

AIM: DX.

DX (Group) plc

("DX" or "the Group" or "the Company")

 

Company Performance Share Plan

 

DX, the provider of delivery solutions, including parcel freight, secure courier and logistics services, reports an amendment ("Amendment") to the Performance Condition of the Company's Performance Share Plan ("PSP"), which was established in December 2017 for directors and certain senior management of the Company ("Participants").

 

The Amendment introduces a further testing date of 21 December 2023, with the objective of retaining and fairly rewarding the 36 Participants, who are currently employed by the Group, in the PSP for a further year. The current third and final testing date for the PSP is on 21 December 2022 and the Amendment therefore extends the Performance Condition and adds a further measurement date in twelve months' time.

 

In light of the close proximity of the date of restoration of the Company's ordinary shares to trading on 19 October 2022 and the third testing date for the PSP under the plan on 21 December 2022, the Amendment creates additional time for the continued strong trading by the Group and its positive outlook to be recognised in a fair market price.

 

The Amendment also provides the further benefit of enabling DX to defer the implementation of a replacement Long Term Incentive Plan for a year and will help to retain and motivate the senior managers in the PSP.

 

A majority of shareholders of the Company's issued share capital, were consulted with respect to the Amendment.

 

Related party transaction

 

Under the AIM Rules for Companies, the Amendment to the PSP in relation to David Mulligan, Paul Ibbetson, Martin Illidge, Michael Sherry, and Kevin Galligan is classified as a Related Party Transaction. Accordingly, Mark Hammond, Mike Russell and Jon Kempster as Independent Directors consider, having consulted with finnCap, the Company's Nominated Adviser, that the terms of the Amendment are fair and reasonable insofar as its shareholders are concerned.

 

Enquiries:

DX (Group) plc

T: 020 3178 6378 (c/o KTZ

Jon Kempster, Senior Independent Non-executive Director

 Communications)

Mike Russell, Independent Non-executive Director

finnCap (Nominated Adviser & Joint Broker to DX)

T: 020 7220 0500

Matt Goode/Simon Hicks (Corporate Finance)

Andrew Burdis/Charlotte Sutcliffe (ECM)

 

Liberum (Joint Broker to DX)

T: 020 3100 2000

Nick How/William Hall

 

 

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis

Dan Mahoney

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEANALFELAFEA
Date   Source Headline
6th Feb 20194:40 pmRNSSecond Price Monitoring Extn
6th Feb 20194:35 pmRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Statement
17th Dec 20183:06 pmRNSDirector/PDMR Shareholding
4th Dec 201812:29 pmRNSResult of AGM
4th Dec 20187:00 amRNSAGM Statement
3rd Dec 20187:00 amRNSDirector Disclosure
7th Nov 201811:07 amRNSDirector Declaration
29th Oct 20184:35 pmRNSPrice Monitoring Extension
15th Oct 20187:00 amRNSNotice of AGM
2nd Oct 20183:47 pmRNSPreliminary Results - replacement
2nd Oct 20187:00 amRNSPreliminary Results
14th Aug 20184:40 pmRNSSecond Price Monitoring Extn
14th Aug 20184:35 pmRNSPrice Monitoring Extension
26th Jul 20187:00 amRNSGrant of share awards and PDMR notification
18th Jul 20187:00 amRNSTrading Update
14th Jun 20187:00 amRNSDirector/PDMR Shareholding
6th Jun 20183:02 pmRNSHolding(s) in Company
25th May 201810:50 amRNSGrant of Share Awards and PDMR Shareholding
24th May 20185:47 pmRNSHolding(s) in Company
23rd May 20188:45 amRNSCompletion of Transaction and Director Dealing
23rd May 20187:00 amRNSDirector/PDMR Shareholding
22nd May 20185:04 pmRNSTotal Voting Rights
22nd May 201811:38 amRNSResult of General Meeting
3rd May 20186:32 pmRNSFundraising and Loan Note Cancellation
29th Mar 20187:00 amRNSInterim Results
21st Mar 20187:00 amRNSAppointment of Chief Financial Officer
19th Mar 20187:00 amRNSNotice of Results
5th Feb 20183:29 pmRNSHolding(s) in Company
29th Jan 20187:00 amRNSChange of Adviser
3rd Jan 20185:15 pmRNSDirector/PDMR Shareholding
22nd Dec 20171:19 pmRNSCompletion of Loan Note issue
22nd Dec 20171:14 pmRNSDirector/PDMR Shareholding
22nd Dec 20171:13 pmRNSGrant of share awards and PDMR notification
18th Dec 201711:09 amRNSHolding(s) in Company
15th Dec 201711:41 amRNSResult of GM
8th Dec 201712:22 pmRNSResult of AGM
28th Nov 20177:00 amRNSRe: GM Notice, Circular and Incentive Awards
14th Nov 20179:00 amRNSPosting of Annual Report & Notice of AGM
27th Oct 201712:07 pmRNSSecond Price Monitoring Extn
27th Oct 201712:02 pmRNSPrice Monitoring Extension
20th Oct 201712:07 pmRNSSecond Price Monitoring Extn
20th Oct 201712:02 pmRNSPrice Monitoring Extension
20th Oct 20177:00 amRNSBoard Changes
20th Oct 20177:00 amRNSPreliminary Results
9th Oct 20177:00 amRNS£24m Fundraising, CEO Appointment & Board Changes
29th Sep 201712:21 pmRNSRe: Property Transaction
28th Sep 20177:00 amRNSMajor New Contract with IKEA
22nd Sep 20177:00 amRNSFinancing Update, Property Disposal, Gatemore Loan
20th Sep 20174:48 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.